Scientists have identified several potential therapeutic targets for amyotrophic lateral sclerosis (ALS) using an artificial intelligence (AI)-powered target discovery engine to analyze dysregulated gene expression in large, publicly available ALS datasets.
Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS Detailed data from the CENTAUR clinical trial were published in the New England Journal of Medicine,Muscle & Nerve, and the Journal of Neurology, Neurosurgery and Psychiatry
Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal genetic form of the disease leading to loss of everyday functions and affecting approximately 2% of people with ALS
ALS Finding a Cure® funded Eledon’s early clinical work for Tegoprubart when the drug was still with ALS TDIAnne D Pham2022-06-15T18:44:42+00:00
IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced topline results from a Phase 2a clinical trial of tegoprubart (formerly AT-1501) in patients with amyotrophic lateral sclerosis (ALS).1
The ALS Association, in collaboration with ALS Finding a Cure, recently awarded $400,000 to support research into the role SARM1 gene mutations play in the development and progression of ALS, with the ultimate goal of using an improved understanding of SARM1 to develop new treatments. The research will be led by Dr. Jemeen Sreedharan at King’s College London and Dr. Michael Coleman at Cambridge University.
Motor neuron toxin associated with ALS identified by UMass Chan investigators An international team of investigators has discovered that an inorganic polyphosphate released by nerve cells known as astrocytes in people with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) contributes to the motor neuron death that is the signature of these diseases. The research, by Brigitte van Zundert, PhD, adjunct professor of neurology at UMass Chan and professor at the Universidad Andres Bello in Chile; Robert H. Brown Jr., DPhil, MD, professor of neurology, and colleagues appears this week in Neuron.